NCT02094560 (CAP7-1) is a Phase 2 clinical trial of CAP7.1 in Advanced Endstage Solid Carcinomas in Adults, sponsored by CellAct Pharma GmbH.

Who is sponsoring NCT02094560?

NCT02094560 is sponsored by CellAct Pharma GmbH.

What drugs are being tested in NCT02094560?

Interventions in NCT02094560: CAP7.1.

What condition does NCT02094560 study?

NCT02094560 studies Advanced Endstage Solid Carcinomas in Adults.

Is NCT02094560 still recruiting?

NCT02094560 is currently terminated. Last updated 5 September 2018.

Last reviewed 2018-09-05 · How we verify

NCT02094560: CAP7-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors

Terminated Phase 2 Last updated 5 September 2018

What this trial tests

Phase 2 trial testing CAP7.1 in Advanced Endstage Solid Carcinomas in Adults in 45 participants. Terminated before completion.

Timeline

8 November 2011

Primary endpoint
8 September 2015

10 April 2017

Quick facts

Lead sponsor	CellAct Pharma GmbH
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	8 November 2011
Primary completion	8 September 2015
Estimated completion	10 April 2017
Sites	1 location across Germany

Drugs / interventions tested

CAP7.1 — full drug profile →

Conditions studied

Advanced Endstage Solid Carcinomas in Adults — all drugs for Advanced Endstage Solid Carcinomas in Adults →

Sponsor

CellAct Pharma GmbH — full company profile →

Who can join

Eligibility, any sex, with Advanced Endstage Solid Carcinomas in Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and rate of disease stabilization, as defined by the below primary and secondary endpoints, in patients with Non-Small Cell Lung Carcinoma (NSCLC), SCLC or biliary cancer who have progressed despite one or more previous chemotherapy line.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study.
Pape UF, Kasper S, Meiler J, Sinn M, et al · · 2020 · cited 2× · PMID 33121007 · DOI 10.3390/cancers12113149

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02094560 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CellAct Pharma GmbH
Last refreshed: 5 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02094560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing